One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Lannett Company logo
Lannett Company LCI
report update icon

Quarterly report 2023-Q3
added 06-13-2026

Lannett Company Income Statement 2022-2009 | LCI

Brief overview of financial results at Lannett Company

The comparison covers a five-year financial horizon. The revenue attributed to Lannett Company moved from 184 million dollars to 341 million dollars between the two endpoints. The total change was +84.8%, with a CAGR of approximately 13.1%. Top-line growth remained consistently strong over the period.

Gross profit changed from $87.5 million to $33.2 million (−62.1%). Direct costs outpaced revenue, limiting the benefit of changes in sales. The gross margin was 47.4% at the start and 9.7% at the end. The business retained less gross profit from each unit of revenue.

EBITDA was 102 million dollars at the beginning and −142 million dollars at the end of the period (−238.6%). Changes in revenue did not translate into comparable EBITDA performance. EBITDA margin was 55.6% at the start and −41.7% at the end. The margin contraction indicates weaker operating efficiency.

The final result was 14 million dollars initially and −232 million dollars in the final year. The move from profit to loss indicates a material deterioration in final efficiency.

Over the period, capitalization shifted from $854 million to $23 million (−97.3%). The market has not yet confirmed the improvement in fundamentals.

Overall conclusion

The financial trajectory is weak and requires a cautious interpretation. The financial profile benefits from revenue expansion. The overall view is constrained by weaker operating efficiency, a lower gross margin and lower net income. Investors should continue to monitor margins, costs, and earnings quality.

Annual Income Statement Lannett Company

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009

Market Cap

23 M 63.8 M 252 M 333 M 184 M 854 M 804 M 1.44 B 1.44 B 942 M 140 M 118 M - -

Shares

40.4 M 39.4 M 38.6 M 37.8 M 37.1 M 36.8 M 36.4 M 35.8 M 33.7 M 28.5 M 28.3 M 26.8 M 24.7 M -

Historical Prices

0.57 1.62 6.52 8.82 4.96 23.2 22.1 40.1 42.9 33.1 4.96 4.42 - -

Net Income

-232 M -363 M -33.4 M -272 M 12.4 M 14 M 44.9 M 150 M 57.2 M 13.4 M 4.02 M -240 K 8.01 M 55 K

Revenue

341 M 479 M 546 M 655 M 194 M 184 M 171 M 407 M 274 M 151 M 123 M 107 M - -

Cost of Revenue

294 M 378 M 98.3 M 94.8 M 124 M 96.9 M - 27.3 M 27.6 M 26.3 M 23.7 M 20.3 M 21.7 M 20.6 M

Gross Profit

33.2 M 75.6 M 165 M 244 M 69.8 M 87.4 M 88.1 M 71.6 M 87.2 M 41 M 13.4 M 7.43 M 8.36 M 8.08 M

Operating Income

-176 M -237 M 19.6 M -262 M 36.7 M 47.1 M 34.3 M 30.3 M 66.5 M 25.4 M 4.69 M 495 K 3.82 M 1.3 M

Interest Expense

58 M 53.8 M 66.8 M 84.6 M 85.6 M 89.4 M 65.9 M 207 K 130 K 251 K 273 K 214 K 276 K -62 K

EBITDA

-142 M -189 M 75.9 M -207 M 91.8 M 102 M 67.7 M 35.9 M 72.5 M 31.6 M 10.4 M 5.47 M 8.71 M 1.3 M

Operating Expenses

209 M 313 M 146 M 506 M 33.1 M 40.3 M 53.7 M 41.3 M 20.7 M 15.7 M 8.73 M 6.93 M 4.54 M 6.78 M

General and Administrative Expenses

81 M 68.1 M 79.5 M 87.6 M 82.2 M 73.5 M 68.3 M 45.2 M 38.6 M 22.4 M 20.2 M 15.9 M 17.4 M -

All numbers in USD currency

Quarterly Income Statement Lannett Company

2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

10.3 M 41.2 M 40.9 M 41.2 M 40.5 M 40.4 M 39.9 M 40.4 M 39.5 M 39.4 M 39.1 M 39.4 M 38.7 M 38.6 M 38.3 M 38.6 M 37.8 M 37.8 M 37.6 M 37.8 M 37.1 M 37.1 M 37 M 37.1 M 36.8 M 36.8 M 36.7 M 36.8 M 36.5 M 36.4 M 36.3 M 36.4 M 35.9 M 35.7 M 35.6 M 35.7 M 35 M 34.7 M 29.6 M 34.7 M 28.5 M 28.3 M 28.3 M 28.3 M 28.6 M 28.5 M 28.4 M 28.5 M 28.4 M 28.5 M 28.4 M

Net Income

-101 M -36.3 M -28 M -36.3 M -34.9 M -81.1 M -22.3 M -81.1 M -7.14 M -172 M -6.5 M -172 M -16.6 M 5.08 M -12.2 M 5.08 M -265 M -275 M -288 M 12.4 M 12.8 M 14 M 13.3 M 14 M 14.9 M 8.19 M -29.4 M 8.19 M -5.47 M 13.5 M 33.2 M 13.5 M 36.3 M 44.8 M 35 M 44.8 M 23 M 16.6 M -5.99 M 16.6 M 3.96 M 2.86 M 2.94 M 2.86 M 1.73 M 630 K 222 K 630 K 222 K 630 K 222 K

Revenue

80.5 M 80.9 M 75.1 M 80.9 M 78.4 M 86.5 M 102 M 86.5 M 112 M 134 M 126 M 134 M 144 M 136 M 127 M 136 M 173 M 194 M 155 M 194 M 155 M 194 M 174 M 184 M 155 M 339 M 162 M 171 M 162 M 171 M 162 M 127 M 106 M 127 M 106 M 115 M 93.4 M 115 M 93.4 M 67.3 M 45.8 M 67.3 M 45.8 M 36.6 M 35.3 M 36.6 M 35.3 M 27.7 M 28.9 M 27.7 M 28.9 M

Cost of Revenue

64.3 M 65.3 M 61.3 M 65.3 M 72.7 M 77 M 81 M 77 M 82.1 M 124 M 92.2 M 124 M 94.4 M 86.7 M 77.7 M 94.8 M 84.7 M 84.5 M 107 M 124 M 95.9 M 104 M 107 M 96.9 M 87.3 M - - - - - - - 23.7 M 27.6 M 21.8 M 27.6 M 23.9 M 26.3 M 24.4 M 26.3 M 23.3 M 22.6 M 21.2 M 23.1 M 19.3 M 19.8 M 19.7 M 20.3 M 20.3 M 21.8 M 20.6 M

Gross Profit

15.2 M 14.3 M 12.6 M 14.3 M 3.08 M 5.71 M 16.5 M 5.71 M 26.5 M 775 K 25.7 M 775 K 41.7 M 41.3 M 42.7 M 41.3 M 65.3 M 69.8 M 59.1 M 69.8 M 67.1 M 87.4 M 67.7 M 87.4 M 72.4 M 88.1 M 81.9 M 88.1 M 57.5 M 71.6 M 77.4 M 71.6 M 75.6 M 87.2 M 71.6 M 87.2 M 56.1 M 41 M 1.31 M 41 M 15.2 M 13.4 M 13.6 M 13.4 M 10.9 M 7.43 M 8.62 M 7.43 M 8.62 M 7.43 M 8.62 M

Operating Income

-86.7 M -14.8 M -13 M -14.8 M -22.1 M -68.1 M -8.15 M -68.1 M 2.85 M -217 M -15 K -217 M -2.09 M 16.8 M 9.4 M 16.8 M 33.4 M 36.7 M -342 M 36.7 M 33.3 M 47.1 M 40.7 M 47.1 M 43.6 M 34.3 M -20.3 M 34.3 M 18.6 M 30.3 M 51.4 M 30.3 M 54.3 M 66.5 M 54.7 M 66.5 M 36 M 25.4 M -10.6 M 25.4 M 4.7 M 4.69 M 3.69 M 4.69 M 2.36 M 495 K 1.45 M 495 K 1.44 M 495 K 1.45 M

Interest Expense

15.2 M 15.2 M 15 M 15.2 M 14.5 M 14.4 M 14.2 M 14.4 M 12.6 M 13.5 M 14.5 M 13.5 M 16.2 M 16.7 M 19.3 M 16.7 M 21.5 M 21.5 M 21.4 M 21.5 M 22.8 M 20.7 M 20.9 M 20.7 M 22.4 M 23.3 M 23 M 23.3 M 27 M 11.8 M 60 K 11.8 M 8 K 73 K 38 K 73 K 13 K 46 K 58 K 46 K 59 K 72 K 63 K 72 K 63.7 K 72.7 K 77 K 73 K 77 K 72.7 K 77 K

EBITDA

-67.3 M -2.27 M -6.81 M -9.87 M 4.58 M -49.2 M 1.44 M -62.6 M 41.2 M -188 M 14.3 M -211 M 39.3 M 43.7 M 22.2 M 22.7 M 75.4 M 65.3 M -327 M 42.4 M 73.9 M 74.5 M 54.5 M 52.5 M 85.2 M 62.3 M -5.99 M 39.8 M 38.7 M 38.4 M 53.3 M 32.7 M 58.3 M 69.2 M 56 M 67.8 M 40.8 M 28.5 M -9.04 M 26.5 M 9.32 M 7.78 M 5.24 M 5.79 M 6.57 M 3.3 M 2.86 M 1.41 M 2.86 M 3.3 M 2.86 M

Operating Expenses

102 M 29 M 25.6 M 29 M 25.2 M 73.8 M 24.7 M 73.8 M 23.6 M 217 M 25.7 M 217 M 43.8 M 24.5 M 33.3 M 24.5 M 31.9 M 33.1 M 401 M 33.1 M 33.8 M 40.3 M 27 M 40.3 M 28.8 M 53.7 M 102 M 53.7 M 38.9 M 41.3 M 26 M 41.3 M 21.4 M 20.7 M 16.9 M 20.7 M 20.1 M 15.7 M 11.9 M 15.7 M 11.9 M 15.7 M 11.9 M 8.73 M 9.94 M 9.41 M 8.53 M 6.93 M 7.17 M 7.19 M 6.13 M

General and Administrative Expenses

20.4 M 18.3 M 16.7 M 18.3 M 17.6 M 18.8 M 18.9 M 18.8 M 17.6 M 13.7 M 15.1 M 13.7 M 22.1 M 17.4 M 21.3 M 17.4 M 21.6 M 23.2 M 20.6 M 23.2 M 14.1 M 28.5 M 19 M 28.5 M 17.6 M 18.1 M 21.3 M 18.1 M 16.2 M 14.7 M 15.5 M 14.7 M 12.2 M 12.8 M 10.6 M 10.8 M 9.56 M 9.89 M 7.18 M 9.89 M 5.24 M 5.16 M 6.17 M 5.16 M 5.62 M 4.42 M 4.74 M 4.42 M 4.74 M 4.42 M 4.74 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company Lannett Company (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Drug manufacturers industry

Issuer Price % 24h Market Cap Country
Perrigo Company plc Perrigo Company plc
PRGO
$ 15.91 -1.64 % $ 2.2 B usaUSA
Cumberland Pharmaceuticals Cumberland Pharmaceuticals
CPIX
$ 8.17 2.64 % $ 121 M usaUSA
Evolus Evolus
EOLS
$ 7.4 0.41 % $ 477 M usaUSA
Tricida Tricida
TCDA
- - $ 3.25 M usaUSA
Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc
AVDL
- - $ 2.06 B franceFrance
DURECT Corporation DURECT Corporation
DRRX
- - $ 50.1 M usaUSA
Aerie Pharmaceuticals Aerie Pharmaceuticals
AERI
- - $ 754 M usaUSA
Endo International plc Endo International plc
ENDP
- - $ 28.9 M irlandaIrlanda
Radius Health Radius Health
RDUS
- - $ 1.42 B usaUSA
Recro Pharma Recro Pharma
REPH
- -4.76 % $ 65.3 M usaUSA
Adamis Pharmaceuticals Corporation Adamis Pharmaceuticals Corporation
ADMP
- 0.86 % $ 117 M usaUSA
Agile Therapeutics Agile Therapeutics
AGRX
- 10.11 % $ 58.2 M usaUSA
Evoke Pharma Evoke Pharma
EVOK
- - $ 36.6 M usaUSA
Alimera Sciences Alimera Sciences
ALIM
- - $ 142 M usaUSA
PLx Pharma PLx Pharma
PLXP
- -27.8 % $ 2.56 M usaUSA
Athenex Athenex
ATNX
- -23.39 % $ 1.76 M usaUSA
Zynerba Pharmaceuticals Zynerba Pharmaceuticals
ZYNE
- - $ 55.5 M usaUSA
Aurora Cannabis Aurora Cannabis
ACB
$ 3.96 -0.25 % $ 217 M canadaCanada
Catalent Catalent
CTLT
- - $ 11.5 B usaUSA
Eagle Pharmaceuticals Eagle Pharmaceuticals
EGRX
- -39.89 % $ 27.7 M usaUSA
OptiNose OptiNose
OPTN
- - $ 1.08 B usaUSA
Emergent BioSolutions Emergent BioSolutions
EBS
$ 6.2 -1.43 % $ 332 M usaUSA
PetIQ PetIQ
PETQ
- 1.64 % $ 400 M usaUSA
Pacira BioSciences Pacira BioSciences
PCRX
$ 36.33 -0.14 % $ 1.62 B usaUSA
Rockwell Medical Rockwell Medical
RMTI
$ 7.08 -2.07 % $ 255 M usaUSA
Solid Biosciences Solid Biosciences
SLDB
$ 6.41 0.16 % $ 561 M usaUSA
Tilray Tilray
TLRY
$ 2.92 -3.63 % $ 327 M canadaCanada
TherapeuticsMD TherapeuticsMD
TXMD
$ 1.9 1.06 % $ 22 M usaUSA
Veru Veru
VERU
$ 2.3 -3.36 % $ 33.7 M usaUSA
Viatris Viatris
VTRS
$ 18.45 -1.07 % $ 21.2 B usaUSA
Harrow Health Harrow Health
HROW
$ 28.24 0.61 % $ 1.04 B usaUSA
Canopy Growth Corporation Canopy Growth Corporation
CGC
$ 0.67 -6.67 % $ 200 M canadaCanada
Organogenesis Holdings Organogenesis Holdings
ORGO
$ 0.99 -2.81 % $ 125 M usaUSA
SCYNEXIS SCYNEXIS
SCYX
$ 3.79 -0.39 % $ 189 M usaUSA
Sundial Growers Sundial Growers
SNDL
$ 1.28 0.39 % $ 330 M canadaCanada
Sonoma Pharmaceuticals Sonoma Pharmaceuticals
SNOA
$ 1.14 -0.87 % $ 1.92 M usaUSA
OrganiGram Holdings OrganiGram Holdings
OGI
$ 0.94 0.38 % $ 89.6 M canadaCanada
cbdMD cbdMD
YCBD
$ 0.38 -2.14 % $ 1.53 M usaUSA
Bausch Health Companies Bausch Health Companies
BHC
$ 6.45 0.55 % $ 2.39 B canadaCanada
Cronos Group Cronos Group
CRON
$ 3.39 3.35 % $ 1.3 B canadaCanada
China Pharma Holdings China Pharma Holdings
CPHI
$ 0.7 -3.78 % $ 3 M chinaChina
Relmada Therapeutics Relmada Therapeutics
RLMD
$ 3.21 -4.46 % $ 127 M usaUSA
HEXO Corp. HEXO Corp.
HEXO
- 2.45 % $ 38.1 M canadaCanada
Calliditas Therapeutics AB (publ) Calliditas Therapeutics AB (publ)
CALT
- -0.1 % $ 2.03 B schwedenSchweden
AcelRx Pharmaceuticals AcelRx Pharmaceuticals
ACRX
- 7.5 % $ 6.35 M usaUSA
Assertio Holdings Assertio Holdings
ASRT
- - $ 150 M usaUSA
Jupiter Wellness Jupiter Wellness
JUPW
- - $ 33.6 M usaUSA
Neoleukin Therapeutics Neoleukin Therapeutics
NLTX
- - $ 193 M canadaCanada
ProPhase Labs ProPhase Labs
PRPH
- - $ 5.07 M usaUSA